FTY720 also has a capacity to inhibit SphK1 enzymatic activity, suggesting that FTY720 is a SphK1 inhibitor and may be a new anticancer agent candidate for ACC. The gene discussed is SPHK1; the disease is adrenal cortex carcinoma.